Biotech IV Monitor

AXSM — Axsome Therapeutics Inc.

$11.4B market cap · 8 upcoming readouts tracked

Clinical trial readout dates for Axsome Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts88 Phase 3
Market cap$11.4B
Cash & investments$314M~24 quarters at last loss rate
Recent 8-K filings1latest 2026-11-02

Upcoming readouts

Phase 3 Solriamfetol 150 mg
Excessive Sleepiness; Shift-work Disorder · NCT06568367
December 2026
Recruiting
Phase 3 Solriamfetol 150 mg
Binge-Eating Disorder · NCT06413433
December 2026
Recruiting
Phase 3 AXS-05 (dextromethorphan-bupropion)
Smoking Cessation · NCT07766655
December 2027
Recruiting
Phase 3 Solriamfetol
Binge-Eating Disorder · NCT06878976
December 2027
Enrolling
Phase 3 Solriamfetol
ADHD · NCT07773883
December 2027
Enrolling
Phase 3 AXS-14 (Esreboxetine)
Fibromyalgia · NCT07398417
March 2028
Recruiting
Phase 3 AXS-14 (esreboxetine)
Fibromyalgia · NCT07637162
May 2028
Enrolling
Phase 3 Solriamfetol Dose A
ADHD · NCT07717892
June 2028
Recruiting

Cash position

Axsome Therapeutics Inc. reported $314M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). Its net loss for that quarter was $13M; at that rate the cash would last about 24 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-02

Discussion

No messages yet. If you follow AXSM, you can start the conversation.
Track AXSM in real time
See live implied volatility for AXSM and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on AXSM
Contact — questions or corrections about AXSM: dukeupt@gmail.com